A.R.T. Advisors’s Accelerate Diagnostics AXDX Stock Holding History

A.R.T. Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,244	Closed	-$472K	–	1349
2019 Q1	$472K	Buy	+2,244	New	+$421K	0.03%	759
2018 Q3	–	Sell	-1,385	Closed	-$308K	–	1396
2018 Q2	$308K	Buy	+1,385	New	+$310K	0.01%	1097
2017 Q4	–	Sell	-998	Closed	-$224K	–	1361
2017 Q3	$224K	Buy	+998	New	+$245K	0.01%	1096
2017 Q1	–	Sell	-1,980	Closed	-$410K	–	1423
2016 Q4	$410K	Buy	+1,980	New	+$470K	0.02%	830
2016 Q3	–	Sell	-1,687	Closed	-$242K	–	671
2016 Q2	$242K	Sell	1,687 -1,291	-43%	-$173K	0.01%	1041
2016 Q1	$427K	Buy	+2,978	New	+$420K	0.02%	915

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

A.R.T. Advisors's AXDX Position: Q2 2019 in Review

A.R.T. Advisors sold out of Accelerate Diagnostics (AXDX) in Q2 2019, closing a stake of 2,244 shares — an estimated $472K sold.

A.R.T. Advisors first reported a position in AXDX in Q1 2016 and held it in 6 quarters. The position peaked at $472K in Q1 2019. 117 funds tracked by Wall St. Rank hold AXDX as of Q2 2019.

A.R.T. Advisors reported no remaining Accelerate Diagnostics position as of Q2 2019 after selling out during the quarter.
A.R.T. Advisors sold 2,244 Accelerate Diagnostics shares in Q2 2019, an estimated $472K.
A.R.T. Advisors first reported a position in Accelerate Diagnostics in Q1 2016 and held it in 6 quarters.
A.R.T. Advisors's Accelerate Diagnostics position peaked at $472K in Q1 2019.
117 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.